Brain Tumors in Pediatrics Resident Education Lecture Series Brain Tumors - Background 20-30% of cancers in children 2500-3000 new diagnoses/year 2nd most common neoplasm Most occur before age 10 years Male/Female = 1.3/1.0 60-70% 5 year survival Relative Incidence of Brain Tumors in Children Table 25-1. Approximate incidence of common CNS tumors in children. Pizzo & Poplack Location – Supra vs. Infra Supratentorial Astrocytoma, low grade Astrocytoma, high grade Ependymoma Mixed glioma Ganglioglioma Oligodendroglioma PNET Choroid plexus tumor Meningioma Germ Cell Tumors Other 25-40% 8-20% 6-12% 2-5% 1-5% 1-5% 1-2% 1-2% 1-2% 1-2% 1-2% 1-3% Location – Supra vs. Infra Infratentorial 45-60% Medulloblastoma (PNET) 20-25% Astrocytoma, low grade 12-18% Ependymoma 4-8% Brain stem glioma, high grade 3-9% Brain stem glioma, low grade 3-6% Other 2-5% Brain Tumors - Signs/Symptoms Increased intracranial pressure - symptoms Headache (am) Nausea/vomiting (am) Double vision Head tilt Decreased alertness Lethargy/irritability Poor feeding, FTT Endocrine dysfunction Unexplained behavior changes - affect, motivation, energy level Brain Tumors – Signs/Symptoms Increased ICP – Signs Papilledema, optic atrophy Loss of vision OFC (head circumference) increased Bulging fontanelles, spreading sutures “Setting sun” sign (Parinaud syndrome) Increased blood pressure, low pulse herniation? Posterior Fossa & Brainstem Tumors - Clinical Features Posterior Fossa primary Ataxia Tremors Dysarthria Stiff neck Papilledema Brainstem primary Extremity weakness Cranial nerve signs – double vision – facial weakness – swallowing dysfunction Hemispheric Tumors – Clinical Features Hemiparesis Hemianopsia Aphasia Seizures Treatment Tumor Type Surgery Medulloblastoma +++ Low grade astro +++ cerebellar +++ optic glioma NO High grade astro/GBM +++ Brain stem glioma (exophytic) Ependymoma +++ Germ cell tumor ? bx XRT CrSp focal ???? ???? +++ focal focal +++ Chemo +++ ------???? ? ? ---+++ Treatment - Surgery In general, needed for diagnosis - exceptions: GCT, BSG Ideal is gross total resection Balance prognosis vs. morbidity Debulking, shunts, reservoirs - for symptom/ICP reduction, therapy Treatment – Radiation Therapy Potential for use in all brain tumors – exceptions: choroid plexus tumors Neuro-axis prophylaxis (cranio-spinal rx) – if tumor disseminates via CSF Concerns for long term effects – – – – – neuro-cognitive hearing secondary cancers endocrine skeletal growth Therapy - Chemotherapy Adjunct therapy in most cases – particularly in GCT, medulloblastoma Of interest in young children – (avoid or prolong XRT) Blood brain barrier may be limiting – Newer studies suggest this may not be so – Local delivery via pumps/reservoir/IT Medulloblastoma/PNET Similar histology, different tumor names based on location. – Therapies vary Medulloblastoma PNET Pineoblastoma - posterior fossa - supratentorial - pineal region median age 5 years M:F = 2:1 propensity to disseminate – 1/3 with metastatic disease at diagnosis Medulloblastoma Prognostic Factors Age - Younger tend to do worse Extent of resection Non-posterior fossa tumors Non-localized disease Standard risk High risk 70-80% 5 yr survival 50% what are risk groups? Medulloblastoma CSF dissemination – check for leptomeningeal spread – brain/spine MRI, LP Can spread to lung, liver, BM, bone, LN’s – rare Difference between supratentorial PNET (sPNET), medulloblastoma, and pineoblostoma? Ependymoma 10% of childhood brain tumors Median age = 3-4 yrs 2/3 of primary in posterior fossa May have leptomeningeal spread of brain/spine, CSF Prognostic factors: – Extent of resection!!! – Age: some reports of better survival if > 5-7 years at diagnosis – Histology - MRI Ependymoma - continued Extent of resection most important – Near to gross total resection 50-75% – Less than NTR 0-30% Radiation therapy helps survival – Reduces local recurrence Chemotherapy has not shown efficacy Recurrence is rarely fixable Brain Stem Gliomas Diffuse intrinsic pontine gliomas – median survival = 6-9 months – death within 2 years > 90% – Radiation - transient clinical improvement Low grade gliomas – tectal, exophytic, extra-medullary – highly enhancing on MRI – more indolent Low Grade Astrocytoma/Glioma 30-35% of CNS tumors – 40-50% supratentorial, virtually anywhere M:F = 2:1 Association with NF-1 – more indolent course GTR >90% 5 year survival RX – Radiation – Chemo if symptomatic, progressive, or recurrent Brain Tumors in < 3 year olds 60-70% supratentorial XRT has significant neuro-cognitive effects Goal of therapies: – Delay XRT to at least 3 yrs old with chemotherapy most relapse prior to XRT Current study – – – – Short course (16 wks) chemo 2nd look surgery Focal (conformal) XRT Maintenance chemotherapy Complications From Tumor/Therapy Neurological deficits – limb paresis • Rehab/PT/OT, support – swallowing/speech dysfunction • ENT, Speech therapy • Nutrition issues – neuro-cognitive deficits • School/education issues • Social interaction issues – endocrine dysfunction – end-organ damage • kidney, liver, hearing, neuropathy From ABP Certifying Exam Content Outline Recognize the signs and symptoms of craniopharyngioma Recognize the clinical manifestations of brain tumor Recognize the physical characteristics of a headache due to increased intracranial pressure Differentiate the clinical manifestations of spinal cord compression (eg, from a tumor) from those of other myelopathies, and evaluate appropriately Credits Sachin Jogal MD